Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated that in BRAF V600E mutant cancers, BRAF inhibition can lead to rapid EGFR-mediated feedback activation [95,96,104].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
Items 801–900 of 916
Korshunov, D. A., Bukterov, M. V., Milto, I. V., & Кондакова, И. В. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.13
THE ROLE OF NUTRITIONAL RESTRICTION IN THE PATHOGENESIS OF MALIGNANT TUMORS
Fefelova, Y. A. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.5
THE ROLE OF THE SYSTEM OF INSULIN-LIKE GROWTH FACTORS IN BLOOD IN SOFT TISSUE SARCOMAS
Goroshinskaya, I. A., Kaplieva, I. V., Алексановна, С. С., Frantsiyants, E. M., Vashchenko, L. N., Pogorelova, Y. A., Trepitaki, L. K., Ausheva, T. V., & Витальевич, Ч. П. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.27
MITOCHONDRIAL DYSFUNCTION UNDER THE GROWTH OF B16/F10 MELANOMA IN C57BL/6 MICE
Kit, O. I., Frantsiyants, E. M., Neskubina, I. V., Kaplieva, I. V., Shikhlyarova, A. I., Trepitaki, L. K., Nemashkalova, L. A., & Pogorelova, Y. A. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.9
PLASMONIC PHOTOTHERMAL THERAPY IN EXPERIMENTAL ONCOLOGY: PROBLEMS AND PROSPECTS
Bucharskaya, A. B., Maslyakova, G. N., Наволокин, Н. А., Мудрак, Д. А., Khlebtsov, N. G., Khlebtsov, B. N., Genin, V. D., Genina, E. A., & Tuchin, V. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.16
EFFECACY OF ANTISENSE OLIGONUCLEOTIDE HUSH-11 WITH THIOPHOSPHATE IN TREATMENT OF MELANOMA IN MICE
Yurchenko, K. A., & Oberemok, V. V. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.21
DISCOVERY OF ADAPTATIONAL REACTIONS: A NEW MILESTONE IN THE DEVELOPMENT OF ONCOLOGY
Shikhlyarova, A. I. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.1
NEW CHALLENGE TO CANCER AND LONGEVITY
Inui, T. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.2
Kudriashov, G., Tochilnikov, G. V., Zmitrichenko, Y. G., Krylova, Y. S., Nefedov, A. O., Догонадзе, М. З., Zabolotnykh, N. V., Dyakova, M., Esmerdyaeva, D. S., Vitovskaya, M. L., et al. (2022) · Cardiometry · doi:10.18137/cardiometry.2022.24.conf.10
Capparelli, C., Purwin, T. J., Heilman, S. A., Chervoneva, I., McCue, P. A., Berger, A. C., Davies, M. A., Gershenwald, J. E., Krepler, C., & Aplin, A. E. (2023) · doi:10.1158/0008-5472.22419945
Capparelli, C., Purwin, T. J., Heilman, S. A., Chervoneva, I., McCue, P. A., Berger, A. C., Davies, M. A., Gershenwald, J. E., Krepler, C., & Aplin, A. E. (2023) · doi:10.1158/0008-5472.22419945.v1
Wang, V. E. H., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2023) · doi:10.1158/1078-0432.c.6527784
Self-citationData from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., de la Cruz, F. F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2023) · doi:10.1158/1078-0432.c.6529850.v1
Data from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., de la Cruz, F. F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2023) · doi:10.1158/1078-0432.c.6529850
Lizotte, P. H., Hong, R., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N. A., Yang, A., Kulkarni, M. M., et al. (2023) · doi:10.1158/2326-6066.c.6549088.v1
Merat, R. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101722
Targeting transcriptional addiction in cutaneous melanoma
Cigrang, M. (2023) · theses.fr (ABES) · doi:10.70675/32a61798z3cd7z4cd8za2acza750367acaf5
Zhang, Q., Liu, F., Qin, L., Liao, Z., Song, J., Liang, H., Chen, X., Zhang, Z., & Zhang, B. (2021) · Figshare · doi:10.6084/m9.figshare.14955957
Brosseau, S. (2023) · theses.fr (ABES) · doi:10.70675/c8d2f3dezc12dz4e84z86caze274f14e37bb
Exploring the mechanisms of early acquired resistance to doxorubicin in melanoma spheroidsPreprint
Negrea, G., Pavel, I. O., Bălăcescu, L., Dume, B.-R., Licărete, E., Rauca, V. F., Pătraș, L., Meszaros, S., Dragan, S., Toma, V. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.07.646990
Wei, B., Verdi, V., Zhang, S., Mock, B. A., Shive, H. R., & Simpson, R. J. (2025) · Cancers · doi:10.3390/cancers17142357
Prognostic Implications of Acquired Genetic Changes in Uveal Melanoma
Koopmans, A. E. (2015) · EUR Research Repository (Erasmus University Rotterdam)
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721543
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25844422
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721516
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721552
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721528
Chen, J., Zhai, J., Li, M., Liu, S., Gong, X., Yu, H., Wei, H., & Chen, W. (2024) · Figshare · doi:10.6084/m9.figshare.26567438
Yang, H., Xiao, X., Zeng, L., Zeng, H., Zheng, Y., Wang, J., Li, G., Dai, W., He, Y., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25139606
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721519
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721522
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721534
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721537
Zhang, Q., Liu, F., Qin, L., Liao, Z., Song, J., Liang, H., Chen, X., Zhang, Z., & Zhang, B. (2021) · Figshare · doi:10.6084/m9.figshare.14955954
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721546
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721531
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721513
The role of SOX2 in resistance towards targeted therapy
Hüser, L. (2018) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00024785
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721549
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25844526
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721525
On the origin of melanoma targeted therapy resistance
Raaijmakers, M. I. G. (2017) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-204950
Chen, J., Zhai, J., Li, M., Liu, S., Gong, X., Yu, H., Wei, H., & Chen, W. (2024) · Figshare · doi:10.6084/m9.figshare.26567435
Kot, M., Simiczyjew, A., Wądzyńska, J., Ziętek, M., Matkowski, R., & Nowak, D. (2024) · Figshare · doi:10.6084/m9.figshare.26942661
Ponzone, L., Audrito, V., Landi, C., Moiso, E., Levra Levron, C., Ferrua, S., Savino, A., Vitale, N., Gasparrini, M., Avalle, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26721540
Martinkova, L., Zatloukalová, P., Kucerikova, M., Friedlová, N., Tylichová, Z., Zavadil-Kokas, F., Hupp, T. R., Coates, P. J., & Vojtesek, B. (2024) · Figshare · doi:10.6084/m9.figshare.26952316
Kot, M., Simiczyjew, A., Wądzyńska, J., Ziętek, M., Matkowski, R., & Nowak, D. (2024) · Figshare · doi:10.6084/m9.figshare.26942664
Uncovering a tumor intrinsic role of PD-L1 in triple negative breast cancer
Kong, T. (2018) · eScholarship@McGill (McGill) · doi:10.82308/26355
The role of the MIT/TFE family in melanoma
Dias, D. B. (2024) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/s0at-ga54
Focal Adhesion and Cancer Cell Cycle-Associated Resistance
Ruksha, T. G., Palkina, N. V., Lapkina, E. Z., & Liu, K. (2025) · ACS Omega · doi:10.1021/acsomega.5c07017
MELK controls tumor metabolism to promote resistance to melanoma therapyPreprint
Silva, A. C. B. S., Abbe, P., Pagnotta, S., Amoêdo, N. D., Torno, M. D., Bonnard, F., Botton, T., Larbret, F., Ronco, C., Montaudié, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.31.697178
“Therapy resistance in melanoma is multifactorial, involving both cell-intrinsic mechanisms and microenvironmental influences 28,29 .”
Self-citationWeichenthal, M., Gavrilova, I., Mohr, P., Özdemir, B. C., Asher, N., Ellebæk, E., Ulrich, J., Kreuter, A., Popović, A. D., Ruhlmann, C. H. B., et al. (2026) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2026.100776
Self-citationAbou‐Hamad, J., Delisle, S., Garland, B., Hersi, M., Cook, D. P., & Sabourin, L. A. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120118
Cancer, collapse, and the politics of somatic evolution
Salzet, M. (2026) · Evolution Medicine and Public Health · doi:10.1093/emph/eoag004
“They keep malignant lineages alive until more durable genetic solutions arise [55, 58---60].”
Targeting store-operated Ca2+ entry as a novel strategy to overcome treatment resistance in melanoma
Gutiérrez, D. M. V., Niemeyer, B. A., Kreis, S., & Bréchard, S. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189548
ERKed by too much signaling: from oncogenic driver to therapeutic vulnerability
Farnsworth, D., Naznin, F., Subramaniam, A., Sew, K., & Lockwood, W. W. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06084-6 · Cited by 1
“Another study by Sun and colleagues highlighted how EGFR upregulation, a separate mechanism of resistance to vemurafenib [157], was also only tolerated in the presence of vemurafenib [158].”
An alginate-based 3D cell culture model as a useful tool for melanoma drug testing
Eckert, C., Schmidt, S. K., Sandor, E., Karimi, T., Arkudas, A., Kengelbach‐Weigand, A., & Bosserhoff, A. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119275
Marqueurs prédictifs de réponse aux inhibiteurs de BRAF dans le mélanome cutané métastatique
Funck-Brentano, E. (2016) · theses.fr (ABES) · doi:10.70675/73a2af67z6d03z483czb461zb0527aec1a30
Étude du rôle des facteurs de transcription inducteurs d’EMT dans la mélanomagenèse
Richard, G. (2015) · theses.fr (ABES) · doi:10.70675/5e2b524dzca34z4777zb472z5368743bb211
Rôle de la kinase Akt dans la chimiorésistance : Régulation de l’équilibre Apoptose-Sénescence
Vétillard, A. (2015) · theses.fr (ABES) · doi:10.70675/d0db61dazb197z42dczbb98z6f0276f570b6
Régulation de l'expression de ligands de l'immunité par la voie Rho/ROCK sur les mélanomes
Teiti, L. (2015) · theses.fr (ABES) · doi:10.70675/543ca0cdze0c6z4760z9cc1zdd378ecfab44
Rôle pro-tumorigénique de HACE1 dans le mélanome
Hachem, N. E. (2017) · theses.fr (ABES) · doi:10.70675/c29467dezf843z4a4cz91a8z8b39a51c97c6
Les cellules sénecentes comme niche de survie : rôle de la voie TSP1-CD47
Moreau, M. (2017) · theses.fr (ABES) · doi:10.70675/e62d69b6z1f00z4f88z817bzda54e624150f
Rodrigues, M. J. (2018) · theses.fr (ABES) · doi:10.70675/5324f18az84f8z46d5z8365zd1bc1666321d
Rôle de la tyrosine kinase SYK dans la régulation du processus métastatique du mélanome
García, É. (2016) · theses.fr (ABES) · doi:10.70675/4a5e9fccz0f4fz4dbdza20az51eb44c72718 · Cited by 2
Identification et modulation des voies moléculaires impliquées dans l’agressivité du mélanome cutané
Gautron, A. (2019) · theses.fr (ABES) · doi:10.70675/b9c75939z7407z49abzafcbze6e92703d459
Moya‐Plana, A. (2020) · theses.fr (ABES) · doi:10.70675/951feb6cz54bez4481zb3a9z590aa53175b4 · Cited by 1
Étude et identification des états transcriptionnels dans le mélanome uvéal primaire
Pandiani, C. (2020) · theses.fr (ABES) · doi:10.70675/5d177eeaz698bz4c28z8015za4cfbbfd873d
PHI-501, a dual inhibitor of RAF and DDR1/2, overcomes MAPK drug resistance in Melanoma
Kim, S. M., Cho, S., Sung, G., Nam, K., Yoon, J., Sim, T., Ahn, J. B., & Shin, S. J. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04271-w
“…typically transient, with most patients developing resistance within 12–15 months through MAPK pathway reactivation (via secondary RAS mutations, BRAF splice variants, or amplification), compensatory PI3K–AKT signaling, alternative RTK upregulation, and tumor microenvironment remodeling [32, 33].”
Deolankar, S., & Wermeling, F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.02.716070
“Strong correlations among MAP2K2, MAPK1, and SOX10 are consistent with the published literature linking SOX10 suppression to tolerance to MAPK-202 targeting therapy (26,27).”
Rôle de c-Jun dans la réponse aux inhibiteurs de la voie des MAPK dans les mélanomes
Pohorecka, M. (2018) · theses.fr (ABES) · doi:10.70675/4cf7db7bz9142z4de8zbcbbzd5860991d571
Brunet, L. (2021) · theses.fr (ABES) · doi:10.70675/a4e459eez153dz4ec7z924fza1c1c6e4fdd6 · Cited by 1
Lecacheur, M. (2021) · theses.fr (ABES) · doi:10.70675/9c0b4d17zd8d8z498ezb534z3096acf22d56
Bondarenko, M. (2021) · theses.fr (ABES) · doi:10.70675/b6c8631azd6aaz42e9z9cf3z65208b9697a3 · Cited by 2
Importance de l'axe AhR/Src dans la reprogrammation des mélanomes métastasiques
Paris, A. (2021) · theses.fr (ABES) · doi:10.70675/aa73ebffz8914z40bazb170z7d5c3e02bc0f
The RNA-binding activity of glycolytic enzymes in melanoma
Dian, A. L. (2024) · theses.fr (ABES) · doi:10.70675/87c266aez3679z44a0zbaf9zd2d96fcdb106
Non-genetic regulation of chemopersistence in Triple Negative Breast Cancers
Baudre, L. (2024) · theses.fr (ABES) · doi:10.70675/6422f0bbza832z4dcfza920zaa55605f8a31
Marret, G. (2023) · theses.fr (ABES) · doi:10.70675/fe5bbd3fzfc82z43ffz9c6dzf2c8d40c19dd
Alfahed, A., Alahmari, A. A., & Alasiri, G. A. (2026) · Biology · doi:10.3390/biology15090689 · Cited by 1
“For instance, adaptive resistance mediated by pathway reactivation and compensatory signalling has been shown to be overcome by concurrent inhibition of parallel pathways or multiple receptor tyrosine kinases in preclinical models [56].”
Seong, J., Kim, M. U., Park, H. H., Choi, S., Mack, D. L., Joo, J., & Lee, J. H. (2026) · Acta Biomaterialia · doi:10.1016/j.actbio.2026.05.049
Fan, Z., Mei, Y., Liu, K., Zhang, Y., & Shi, L. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156613
Metadata
- Authors
- Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F. A., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. M., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Institut Gustave Roussy (FR)
- Candiolo Cancer Institute (IT)
- IFOM (IT)
- ORCID
- Sun, Chong
- Wang, Liqin
- Huang, Sidong
- Heynen, Guus J. J. E.
- Prahallad, Anirudh
- Robert, Caroline
- Haanen, John
- Blank, Christian
- Wesseling, Jelle
- Willems, Stefan M.
- Zecchin, Davide
- Lieftink, Cor
- Hofland, Ingrid
- Schlicker, Andreas
- Wessels, Lodewyk F. A.
- Beijersbergen, Roderick L.
- Bardelli, Alberto
- Eggermont, Alexander M. M.
- Venue
- Nature
- Published
- 2014-03-26
- Volume
- 508
- Issue
- 7494
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985928174
- Cited by
- 888
- References
- 30
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 62 · 2023: 58 · 2022: 90 · 2021: 81 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 83 · 2016: 71 · 2015: 107 · 2014: 39
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP130540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- BRAF inhibitor resistance, SOX10, TGF-beta signaling, PDGFRβ, oncogene-induced senescence, drug holidays, MEK inhibitors, adaptive resistance, shRNA screen, cell proliferation, tumor heterogeneity, drug re-sensitization, receptor tyrosine kinase
- MeSH terms
- Vemurafenib, Animals, Antineoplastic Agents, Female, Flow Cytometry, Humans, Indoles, Melanoma, Sulfonamides, Signal Transduction, Gene Library, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Cellular Senescence, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, SOXE Transcription Factors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.